九强生物
(300406)
| 流通市值：73.74亿 | | | 总市值：102.74亿 |
| 流通股本：4.22亿 | | | 总股本：5.88亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,741,626,675.37 | 1,233,685,019.6 | 816,327,794.28 | 373,395,954.06 |
| 营业收入 | 1,741,626,675.37 | 1,233,685,019.6 | 816,327,794.28 | 373,395,954.06 |
| 二、营业总成本 | 1,152,367,616.41 | 808,875,161.23 | 541,125,105.91 | 248,450,721.02 |
| 营业成本 | 441,259,980.15 | 300,976,698.29 | 207,517,915.5 | 94,809,175.25 |
| 税金及附加 | 14,968,576.3 | 10,968,070.12 | 7,093,875.76 | 3,629,242.2 |
| 销售费用 | 364,053,463.81 | 270,530,981.61 | 174,249,009.79 | 76,099,678.26 |
| 管理费用 | 126,984,292.29 | 81,487,866.5 | 54,102,210.19 | 25,545,106.3 |
| 研发费用 | 162,898,782.94 | 109,912,038.83 | 74,814,506.24 | 36,221,121.73 |
| 财务费用 | 42,202,520.92 | 34,999,505.88 | 23,347,588.43 | 12,146,397.28 |
| 其中:利息费用 | 46,992,080.57 | 35,187,662.43 | 23,512,997.26 | 11,584,723.81 |
| 其中:利息收入 | 5,187,911.35 | 1,082,609.08 | 794,996.53 | 543,089.59 |
| 加:投资收益 | 20,763,691.84 | 6,674,501.73 | 6,351,121.17 | 2,247,656.12 |
| 资产处置收益 | -3,495,156.98 | -2,441,385.03 | -1,770,710.38 | 439,404.14 |
| 资产减值损失(新) | -3,746,940.6 | - | 0 | 0 |
| 信用减值损失(新) | -26,744,200.79 | -11,429,987.38 | -11,562,843.38 | 0 |
| 其他收益 | 17,839,934.79 | 4,129,987.9 | 3,550,318.81 | 1,778,112.57 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 593,876,387.22 | 421,742,975.59 | 271,770,574.59 | 129,410,405.87 |
| 加:营业外收入 | 81,447.96 | 106,353.3 | 69,824.48 | 54,116.08 |
| 减:营业外支出 | 403,271.12 | 189,020.79 | 164,716.03 | 114,220.93 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 593,554,564.06 | 421,660,308.1 | 271,675,683.04 | 129,350,301.02 |
| 减:所得税费用 | 71,484,904.19 | 53,555,705.86 | 32,342,111.33 | 19,406,635.79 |
| 六、净利润 | 522,069,659.87 | 368,104,602.24 | 239,333,571.71 | 109,943,665.23 |
| 持续经营净利润 | 522,069,659.87 | 368,104,602.24 | 239,333,571.71 | 109,943,665.23 |
| 归属于母公司股东的净利润 | 523,742,821.32 | 371,317,794.78 | 241,568,564.76 | 111,021,507.44 |
| 少数股东损益 | -1,673,161.45 | -3,213,192.54 | -2,234,993.05 | -1,077,842.21 |
| (一)基本每股收益 | 0.9 | 0.63 | 0.41 | 0.19 |
| (二)稀释每股收益 | 0.88 | 0.63 | 0.41 | 0.19 |
| 八、其他综合收益 | 218,516.48 | 406,951.97 | 504,177.12 | -243,119 |
| 归属于母公司股东的其他综合收益 | 160,849.98 | 305,010.5 | 377,880.75 | -182,217.69 |
| 九、综合收益总额 | 522,288,176.35 | 368,511,554.21 | 239,837,748.83 | 109,700,546.23 |
| 归属于母公司股东的综合收益总额 | 523,903,671.3 | 371,622,805.28 | 241,946,445.51 | 110,839,289.75 |
| 归属于少数股东的综合收益总额 | -1,615,494.95 | -3,111,251.07 | -2,108,696.68 | -1,138,743.52 |
| 公告日期 | 2024-03-30 | 2023-10-25 | 2023-08-10 | 2023-04-28 |
| 审计意见(境内) | 标准无保留意见 | | | |